AM Ventures has added KGAL and its management team as shareholders as it seeks to double the $59.5m it has raised for its latest fund.

Marshall Group has exited the provider of anti-money laundering and identity verification software provider in a purchase by AML RightSource.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

The Axel Springer-backed share trading platform developer secured $30m that will fund platform development and customer acquisition.

Immuno-oncology therapy developer Lava Therapeutics has filed for a $100m IPO, having been set up in 2016 to exploit Amsterdam University Medical Centers research.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Funds managed by BlackRock added $40m to the $60m supplied for the drug development technology developer by investors including Novo, Evotec and Bristol Myers Squibb in May.

Biox Biosciences, Novo, Sanofi and Merck & Co are all in line to exit the immuno-oncology therapy developer, which has filed for a $100m initial public offering.

BlackRock has joined the University of Dundee spinout’s series C round, following a $60m first close in May last year.

Sage participated in a $12.6m round for the business banking and accounting software provider that took its total funding above $21m.